Evidence map›Paper›PMID 23794360›Full record

ReviewJournal of physiology and biochemistry2013

Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence.

Silvia Lorente-Cebrián, André G V Costa, Santiago Navas-Carretero, María Zabala, J Alfredo Martínez, María J Moreno-Aliaga

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Journal of physiology and biochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03300388 (Dysfunction of Adipose Tissue in Obesity, Inflammation and Aging), which is not on this map. Cited by 148 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed, 6 pooled it
28.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03300388 nacompletednot on this mapstarted 2017, after this paper: background citation

Dysfunction of Adipose Tissue in Obesity, Inflammation and Aging: Mechanisms and Effects of Physical Exercise and Omega-3 Fatty Acids.

TypeinterventionalSponsorClinica Universidad de Navarra, Universidad de NavarraRan2017 to 2019Enrolled85ConditionsObesity, Aging, InflammationArmsOmega-3 (DHA-rich dietary supplement), Placebo (olive oil), Resistance training
3 · Its place in the literature

Who cites it

148 citing papers in PubMed, 6 syntheses or guidelines pooled it, 411 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Review

88 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Silvia Lorente-CebriánDepartment of Nutrition, Food Science and Physiology, University of Navarra, Pamplona, Spain.
André G V Costa
Santiago Navas-Carretero
María Zabala
J Alfredo Martínez
María J Moreno-Aliaga
Universidad de Navarra · ESSpanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition · ESUniversidade Federal de Viçosa · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present review aims to illustrate current knowledge about the efficacy of omega-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFAs) in treating/preventing several metabolic pathologies. We reviewed systematically the published evidence on the effectiveness of n-3 LC-PUFAs fish consumption or n-3 LC-PUFAs supplementation on prevention/treatment of obesity, metabolic syndrome, and cardiovascular diseases. Most of the reviewed studies were randomized-controlled interventional trials, although some relevant prospective and cross-sectional studies as well as some meta-analysis were also reviewed. Supplementation with n-3 LC-PUFAs might improve some obesity-associated metabolic syndrome features such as insulin resistance, hypertension and dyslipidemia by decreasing plasma triglycerides. Moreover, the blood pressure-lowering and anti-inflammatory properties of these fatty acids and their benefits in vascular function might confer cardioprotection. However, the efficacy of n-3 LC-PUFA on reducing myocardial infarction, arrhythmia, cardiac and sudden death, or stroke is controversial. Due to the beneficial actions of n-3 LC-PUFAs, several worldwide government and health organizations have established some recommendations of n-3 LC-PUFAs intake for groups of population. In general, the recommended levels for diseases prevention are lower than those advised for particular treatments. However, more clinical trials are necessary to recommend the most effective dosages and formulas (type of n-3 LC-PUFA, EPA/DHA ratio) for specific pathologies.

Indexed as

Dietary SupplementsAdipose TissueAnimalsBody WeightCardiovascular DiseasesClinical Trials as TopicFatty Acids, Omega-3HumansInsulin ResistanceMetabolic SyndromeObesityFatty Acids, Omega-3

Identifiers

PMID23794360
OpenAlexW2027442810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.